Inclusion Criteria:

        For Cohorts 1 and 2:

          -  Metastatic melanoma;

          -  A metastatic lesion at least 1.5 cm in diameter that can be removed surgically

          -  Measurable or evaluable disease not including the resected lesion

          -  ECOG PS of 0 or 1 prior to cell harvest

          -  Assessment by the treating physician that ECOG performance status of no higher than 2
             can be maintained at least for the period of cell generation, lymphoablation, cell
             infusion and IL-2 administration (for at least 6 weeks following cell harvest)

          -  Tumor refractory to or progressing following prior PD-1/PD-L1 therapy alone or in
             combination with an anti-CTLA-4 agent

          -  Ability to understand risks and benefits of the treatment and to give informed consent

        Exclusion Criteria:

        For Cohorts 1 and 2:

          -  Received prior cell transfer therapy that included non-myeloablative or ablative
             chemotherapy

          -  Any significant major organ dysfunction (see protocol)

          -  Residual toxicity > gr1 from immune checkpoint inhibitor other than persistent
             endocrinopathy on hormone replacement; all symptoms of prior colitis and enteritis
             must have resolved completely as assessed by history

          -  Any contraindication to neutropenia or thrombocytopenia for up to 2 weeks (no active
             major infection, no site of active, clinically significant bleeding)

          -  Concurrent major medical illnesses

          -  Any form of immunodeficiency

          -  Requirement for steroids > 10 mg prednisone daily or equivalent

          -  Severe hypersensitivity to any of the agents used in this study

          -  Contraindications for IL-2 administration

        At the time of lymphoablation subjects must meet baseline eligibility criteria with the
        following additions and exceptions:

        • Confirmation by lab that cell product can be ready for harvest and infusion within 7 days

        For Cohort 2 only:

        At the time of the start of anti-PD-1/anti-CTLA-4 therapy, subjects must meet baseline
        eligibility criteria with the following additions and exceptions:

          -  Patient cannot have a steroid requirement > 10 mg prednisone daily or equivalent

          -  Patients who have received prior PD-1/PD-L1 antagonist therapy and developed severe
             autoimmune disease precluding further immune checkpoint therapy

          -  Any organ dysfunction that makes the subject ineligible for anti-PD1 and anti-CTLA-4
             treatment as deemed by the treating investigator

          -  ECOG PS of 0-2

          -  Hgb of at least 8.0 gm/dl (may be transfused to this level)

          -  Creatinine not greater than 2.5 mg/dl

          -  AST or ALT not > 5x ULN and total bilirubin not > 2.5 mg/dl

          -  No clinically significant change in major organ function compared to initial
             eligibility evaluation

          -  Prior to initiating the lymphoablation regimen, there can be no untreated brain lesion
             > 1.0 cm, and/or with significant evidence of hemorrhage. Subjects may begin
             lymphoablation no less than 1 full day after completing WBRT or stereotactic
             radiotherapy for brain lesions.